Platelet to high-density lipoprotein cholesterol ratio predicts clinical outcomes after acute ischemic stroke: a prospective cohort study - Scorecard - MDSpire
Advertisement
Platelet to high-density lipoprotein cholesterol ratio predicts clinical outcomes after acute ischemic stroke: a prospective cohort study
Clinical Scorecard: The Ratio of Platelets to High-Density Lipoprotein Cholesterol as a Predictor of Clinical Outcomes Following Acute Ischemic Stroke: Results from a Prospective Cohort Study
At a Glance
Category
Detail
Condition
Acute Ischemic Stroke (AIS)
Key Mechanisms
Platelet/high-density lipoprotein cholesterol ratio (PHR) as a marker of hypercoagulable states and disordered lipid metabolism.
Target Population
Patients with acute ischemic stroke.
Care Setting
Prospective observational study in a hospital setting.
Key Highlights
Higher PHR levels are associated with increased risk of all-cause death and stroke recurrence.
Tertile 3 of PHR shows the highest risk for poor functional outcomes at 3, 6, and 12 months.
Continuous PHR demonstrates a positive dose–response relationship with clinical outcomes.
Guideline-Based Recommendations
Diagnosis
Assess PHR at admission for patients with AIS.
Management
Consider PHR as a predictive biomarker for clinical outcomes in AIS.
Monitoring & Follow-up
Monitor PHR levels and associated clinical outcomes at 3, 6, and 12 months.
Risks
Higher PHR is linked to increased mortality and poor functional outcomes.
Patient & Prescribing Data
820 patients with acute ischemic stroke.
PHR may help identify high-risk patients for targeted interventions.
Clinical Best Practices
Utilize PHR as a simple and effective tool for predicting clinical outcomes in AIS.
